A patient and a pharmacy level drug alert recall has been issued by the Medicines and Healthcare products Regulatory Agency (MHRA) for three specific lots of asthma inhalers as they may not deliver the full number doses
Today (Friday 9 Feburary 2018) marks the precise point that we are a year away until the European Union Falsified Medicines Directive (EU FMD) comes into force. Here, we feature some expert opinions
Here, Vikash Patel, senior regulatory specialist for ELC Group, gives us an update on the regulatory developments impacting the pharma industry as a result of Brexit.
In this article, Michael Adeogun, head of Life Sciences and Health at NPL examines how and where measurement can help government and industry grasp the opportunities the Strategy and Sector Deal offer.
The Brexit Health Alliance (BHA) has urged for regulatory arrangements to be made as a matter of urgency to prevent any potential risk to public health as a result of Brexit.
One of the potential pitfalls when preparing a product launch is planning for GMP inspections. An upside of recent events, is worksharing, leading towards a more globalised market. In this article Vikash Patel, ELC Group tells us more...
In this online exclusive, Stephanie Ward, a quality assurance engineer at technology and product design firm Cambridge Design Partnership looks at the new European MDR in more detail and the impact these may have on manufacturers
STA Pharmaceutical has reported rapid growth in companies intending to market their products in China using it as a partner following the CFDA announcement of the Market Authorization Holder (MAH) pilot programme last year
Despite concern expressed by the pharmaceutical industry that the UK would suffer as a result of Brexit, Catalyst Corporate Finance, the UK business of Alantra, argues that the UK’s decision to leave the European Union in fact
Today (Monday 27 November) marks the original deadline date for the DSCSA. While the FDA has delayed its enforcement of compliance with these serialisation requirements by a year, pharma is still required to legally comply. Industry tells us more…
Following the chancellor’s autumn budget announcement, we provide a brief round-up of the key points and some of the reactions from the pharma and industry leaders.
